Celegence, a global provider of regulatory affairs services for the life sciences industry, is pleased to announce that Navignostics, a global developer of drug mechanisms designed to identify ideal treatments for cancer patients, has selected Celegence’s CAPTIS
Navignostics has been working dedicatedly to leverage unique tumor analysis approaches to improve personalized diagnostics for cancer patients. With highly robust and reliable technology and leading data analytics, Navignostics aims to deliver the optimal cancer treatment for each patient and provide services to pharma and biotech partners.
As the EU’s IVDR directives went into effect this year, diagnostic manufacturers are now pressed by the complex literature review and data management activities required to write PMS documentation to remain compliant. Celegence’s CAPTIS
Punya Abbhi, Chief Operating Officer at Celegence, said: “We are so glad to support Navignostics in the process of EU IVDR PMS documentation. The CAPTIS
“Navignostic’s mission of designing client-oriented personalized solutions resonates with our values. Celegence realizes our client’s unique demands, and we aspire to provide efficient planning and cost-effective solutions through our innovative technologies.”
Dr. Stéphane Chevrier, Co-Founder at Navignostics, said: “We are genuinely excited to work with Celegence and use CAPTIS platform can better support our compliance efforts related to launching and maintaining focused cancer treatments and medications.”
If you would like to learn more about how CAPTIS
Got a Questions?
Find us on Socials or Contact us and we’ll get back to you as soon as possible.